This financing will provide fuel for our growing pipeline as we continue to develop our innovative and differentiated NMDA receptor modulators for the treatment of a variety of neurologic disorders with high unmet medical need, said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

909 Davis St. 600
Evanston, IL 60201
USA

Phone

(847) 871-0377

Website

www.aptinyx.com

Email Address

[email protected]

Overview

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Norbert Riedel

Chief Operating Officer

Ashish Khanna

Chief Scientific Officer

Joseph Moskal

VP - Human Resources

Patricia Adams

VP - R & D

Cassia Cearley

VP - R & D

Amin Khan

Browse more venture capital transactions:

Prev: 12/19/2017: Springboard venture capital transaction
Next: 12/19/2017: Aunt Fannie's venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary